Davis R M Inc. Purchases 805 Shares of Zoetis Inc. (NYSE:ZTS)

Davis R M Inc. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 133,115 shares of the company’s stock after acquiring an additional 805 shares during the quarter. Davis R M Inc.’s holdings in Zoetis were worth $26,008,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ZTS. Caxton Associates LP acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $1,710,000. Silvercrest Asset Management Group LLC grew its holdings in Zoetis by 33.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 12,793 shares of the company’s stock worth $2,165,000 after acquiring an additional 3,193 shares during the period. Bayesian Capital Management LP acquired a new stake in Zoetis during the 1st quarter worth $1,658,000. Kennedy Capital Management LLC bought a new stake in shares of Zoetis during the 1st quarter valued at $883,000. Finally, In Depth Partners LLC lifted its stake in shares of Zoetis by 2.8% in the 1st quarter. In Depth Partners LLC now owns 69,688 shares of the company’s stock valued at $11,792,000 after purchasing an additional 1,867 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $176.96 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The business has a 50 day simple moving average of $185.62 and a 200 day simple moving average of $180.72. The stock has a market cap of $79.84 billion, a price-to-earnings ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.36 earnings per share. Analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ZTS. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.